All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 1 February 2019, Owen O’Connor from Columbia University Medical Centre, New York, NY, USA and colleagues, published in the Journal of Clinical Oncology a phase III study (LUMIERE) investigating the efficacy of alisertib in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) patients.
Alisertib is an investigational Aurora A kinase inhibitor. Aurora A kinase is involved in cell mitosis and accumulating evidence indicates its pathological upregulation in PTCL. From phase I-II studies the recommended dose and treatment pattern of alisertib monotherapy have been established, together with its promising activity in various lymphomas, including R/R B-cell and T-cell lymphomas. The aim of this randomized, multicenter, two-arm, open-label, phase III trial (NCT01482962) was to investigate the efficacy of alisertib monotherapy versus investigator’s choice treatment in R/R PTCL patients. The primary endpoints of this study were overall response rate (ORR), and progression-free survival (PFS). Secondary endpoints included, overall survival (OS), safety, complete response (CR) rate, time-to-progression (TTP), time-to-partial response (TTR), and duration of response (DoR).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox